Peanut Allergy Treatment Market Size Is Expected To Reach USD 992.2 Million By 2030Posted by Neha Bora on September 5th, 2023 San Francisco, 5 Sep 2023: The Report Peanut Allergy Treatment Market Size, Share & Trends Analysis Report By Drug Class (Antihistamines, Epinephrine), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030 The global peanut allergy treatment market size is expected to reach USD 992.2 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 10.44% from 2023 to 2030. Some of the key factors propelling the market growth include a robust product pipeline, high disease prevalence, advancement in the drug delivery system, and strategic initiatives by key players. Key market players are bolstering their pipeline for peanut allergy treatment through various strategies. For instance, Aravax initiated its series B funding round in December 2022, securing a USD 20 million investment from renowned Australian healthcare entrepreneurs Tenmile and Brandon Capital. This financing will enable Aravax to commence phase II clinical trials of PVX108, targeting individuals who experience allergic reactions to peanuts. Such fundings are expected to drive advancements in research and development programs. The market is stimulated by the increasing number of product approvals for peanut allergy treatment. In January 2020, the U.S. Food and Drug Administration (FDA) granted authorization to PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp], developed by Aimmune Therapeutics, Inc. PALFORZIA is the first immunotherapy medication approved for individuals with peanut allergies. It is an oral immune therapy designed to reduce allergy responses, including anaphylaxis triggered by accidental peanut ingestion. It is intended for individuals who have a confirmed allergy, with initial dose escalation recommended for children aged four to 17. As of the first quarter of 2023, several promising pipeline products are undergoing clinical development. These include Viaskin Peanut by DBV Technologies, CA002 by Dupixient, and Camallegr, a collaborative effort between Sanofi and Regeneron. Additionally, other assets such as ADP101, VE416, INP20, and CNP-201 are also in development. The introduction of these medications is anticipated to contribute to the growth and expansion of the market during the projected forecast period. Access Research Report of Peanut Allergy Treatment Market @ https://www.grandviewresearch.com/industry-analysis/peanut-allergy-treatment-market-report Peanut Allergy Treatment Market Report Highlights
Peanut Allergy Treatment Market Report Scope
List of Key Players in the Peanut Allergy Treatment Market
Access Press Release of Peanut Allergy Treatment Market @ https://www.grandviewresearch.com/press-release/global-peanut-allergy-treatment-market Like it? Share it!More by this author |